Press Releases

LENSAR's Assets to be Acquired by a Subsidiary of ALPHAEON Corporation

INCLINE VILLAGE, Nev. , Nov. 11, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference in London , England.  The

INCLINE VILLAGE, Nev. , Nov. 6, 2015 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) issued financial results for the third quarter on Wednesday, November 4, 2015 and has subsequently received numerous inquiries on its reported royalties from royalty rights it acquired from Depomed,

INCLINE VILLAGE, Nev. , Nov. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) today reported financial results for the third quarter and nine months ended September 30, 2015 . Total revenues were $124.6 million for the three months ended September 30, 2015 , compared to $164.6

INCLINE VILLAGE, Nev. , Oct. 28, 2015 /PRNewswire/ --  PDL BioPharma, Inc. (PDL, or the Company) ( NASDAQ : PDLI) today announced that the Company will release its third quarter 2015 financial results for the period ended September 30, 2015 , on Wednesday, November 4, 2015 , after market close.

INCLINE VILLAGE, Nev. , Sept. 23, 2015 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has received approximately $21.4 million in connection with the termination of PDL's structured financing agreement with Avinger, Inc.

INCLINE VILLAGE, Nev. , Sept. 21, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (Nasdaq: PDLI) announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s ("AcelRx") (Nasdaq: ACRX) Zalviso™ (sufentanil sublingual tablet system) in the

INCLINE VILLAGE, Nev. , Sept. 16, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Samuel R. Saks , M.D. has been appointed to the company's board of directors. Dr. Saks serves as a board member for several biotechnology and pharmaceutical companies. Dr.

INCLINE VILLAGE, Nev. , Sept. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 11, 2015 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 4, 2015 , the record date.

INCLINE VILLAGE, Nev. , Sept. 10, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the 6 th Annual Credit Suisse US Small & Mid Cap Conference in New York City next week.

INCLINE VILLAGE, Nev. , Sept. 8, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Paul R. Edick has been appointed to the company's board of directors. Mr. Edick is currently managing partner of 3G Advisors, LLC , a consultancy to the pharmaceutical, healthcare

INCLINE VILLAGE, Nev. , Aug. 5, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2015 . Total revenues were $138.1 million for the three months ended June 30, 2015 , compared to $162.8 million for the

INCLINE VILLAGE, Nev. , July 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) with up to $200 million in revenue

INCLINE VILLAGE, Nev. , July 28, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2015 financial results for the period ended June 30, 2015 , on Wednesday, August 5, 2015 , after market close.

INCLINE VILLAGE, Nev. , June 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby PDL will provide CareView with up to $40 million of secured debt financing.